Who
Paul Campbell
Officer
Company insider
Files Form 4 as: Officer, Viatris; Officer, Mylan II B.V.
In numbers
- Trades disclosed
- 386
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $3.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 5 Feb 2016
- Last trade
- 25 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 26 Jun 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Sold | $810K50,076 at $16.17 | filing |
| 25 Jun 2026filed 26 Jun 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Sold | $810K50,076 at $16.17 | filing |
| 23 Mar 2026filed 24 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Sold | $284K21,350 at $13.28 | filing |
| 23 Mar 2026filed 24 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Sold | $284K21,350 at $13.28 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —27,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $171K12,088 at $14.16 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,371 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,370.62 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —56,727 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $8,510601 at $14.16 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,370.623 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —56,727 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —27,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $171K12,088 at $14.16 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —1,371 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $8,510601 at $14.16 | filing |
| 4 Mar 2026filed 5 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $10K706 at $14.71 | filing |
| 4 Mar 2026filed 5 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —17,108 at $0.00 | filing |
News
Viatris' Dividend Has Room to Grow, but Will Management Deliver?VTRS · insidermonkey.com · 19 Oct 2026Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaVTRS · prnewswire.com · 16 Oct 2026Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?VTRS · insidermonkey.com · 9 Oct 2026
0 headlines in the last 90 days name Paul Campbell; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.